Sailaja Puttagunta - Dec 1, 2023 Form 4 Insider Report for Iterum Therapeutics plc (ITRM)

Role: Chief Medical Officer
Signature: /s/ Sailaja Puttagunta
Stock symbol: ITRM
Transactions as of: Dec 1, 2023
Transactions value $: -$6,218
Form type: 4
Date filed: 12/4/2023, 05:00 PM
Previous filing: Apr 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITRM	Ordinary Shares	Award	$0	+8.33K	+167.7%	$0.00	13.3K	Dec 1, 2023	Direct	F1, F2
transaction	ITRM	Ordinary Shares	Tax liability	-$6.22K	-2.93K	-22.05%	$2.12	10.4K	Dec 1, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITRM	Restricted Share Units	Options Exercise	$0	-8.33K	-33.33%	$0.00	16.7K	Dec 1, 2023	Ordinary Shares	8.33K		Direct	F2, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.
F2	Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.
F3	Represents the ordinary shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted RSUs.
F4	The number of RSUs reported on this Form 4 have been adjusted to reflect the Reverse Share Split.
F5	On December 1, 2021, the reporting person was granted an award of 33,333 RSUs, 25% of which vested on December 1, 2022, with a further 25% having vested on December 1, 2023.